Edgar Filing: Epizyme, Inc. - Form 4

Check this box if no longer subject to Section 16. Form 4 or Form 5		Washington, CHANGES IN SECUR ection 16(a) of the	D.C. 20 BENEF ITIES e Securit ling Con	549 ICIA ties E	LOWNE Exchange A y Act of 1	ERSHIP OF Act of 1934,	OMB Number: Expires: Estimated a burden hour response	•
1. Name and Address of Copeland Robert A	Reporting Person <u>*</u>	2. Issuer Name and Symbol Epizyme, Inc. [E]		Tradi	0	. Relationship of F ssuer	Reporting Pers	on(s) to
(Last) (First C/O EPIZYME, INO TECHNOLOGY SC	t) (Middle) C., 400	3. Date of Earliest Tr (Month/Day/Year) 07/06/2015	-			Director _X Officer (give t elow)		Owner r (specify
(Stree		4. If Amendment, Da Filed(Month/Day/Year	-	1	А	. Individual or Join pplicable Line) X_ Form filed by Or Form filed by Mo	ne Reporting Per	son
(City) (State				C		erson	D	0
1.Title of 2. Transa	ction Date 2A. Deeme Day/Year) Execution I any (Month/Day	d 3. Date, if Transaction Code	4. Securit	ies Ac ed of (equired (A) (D)	red, Disposed of, 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, par value 07/06/2 \$0.0001 per share	015	Code V M <u>(1)</u>		(D)	Price \$ 0.51	(Instr. 3 and 4) 1,250	D	
Common Stock, par value 07/06/2 \$0.0001 per share	015	M <u>(1)</u>	7,121	A	\$ 0.6	8,371	D	
Common 07/06/2 Stock, par	015	S <u>(1)</u>	4,186	D	\$ 22.9046	4,185	D	

Edgar Filing: Epizyme, Inc. - Form 4

value \$0.0001 per share					(2)		
Common Stock, par value \$0.0001 per share	07/06/2015	S <u>(1)</u>	4,185	D	\$ 22.8243 (<u>3)</u>	0	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number prof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration D (Month/Day)	ate	7. Title and Underlying (Instr. 3 and	Securities	8 1 9 ()
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 0.51	07/06/2015		M <u>(1)</u>	1,250	<u>(4)</u>	03/17/2020	Common Stock	1,250	
Stock Option (Right to Buy)	\$ 0.6	07/06/2015		M <u>(1)</u>	7,121	<u>(4)</u>	03/10/2021	Common Stock	7,121	

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Copeland Robert A C/O EPIZYME, INC. 400 TECHNOLOGY SQUARE CAMBRIDGE, MA 02139			President of Research and CSO				

8. De Se (In

Signatures

/s/ Wenlie Zhou, attorney-in-fact

07/08/2015

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$22.70 per share to \$23.01 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the

(2) For share to \$25.00 per share, inclusive. The reporting reason undertakes to provide the issuer, any security notice of the issuer of the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$22.65 per share to \$22.90 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the

- (3) per share to \$22.50 per share, inclusive. The Reporting Person undertakes to provide the issuer, any security holder of the issuer of the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (4) This option is fully vested.

Remarks:

Exhibit List

Exhibit 24 - Confirming Statement

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.